ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Emergent Biosolutions Inc

Emergent Biosolutions Inc (EBS)

8,11
0,36
( 4,65% )
Aktualisiert: 16:17:33

Emergent Biosolutions Inc (EBS) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
8,11
( 4,65% )
Gebot
-
Fragen
-
Volumen
133.007
7,795 Tagesbereich 8,12
5,615 52-Wochen-Bereich 14,06
Marktkapitalisierung
Handelsende
7,75
Handelsbeginn
7,795
Letzte Trade
100
@
8.11
Letzter Handelszeitpunkt
16:17:34
Finanzvolumen
US$ 1.064.472
VWAP
8,0031
Durchschnittliches Volumen (3 Mio.)
US$ 751.714
Ausgegebene Aktien
51.596.296
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-39,08
Gewinn pro Aktie (EPS)
-0,21
Erlöse (LTM)
676,8M
Nettogewinn (LTM)
-8,6M

Über Emergent Biosolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues... Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Hauptsitz
Gaithersburg, United States
Gegründet
1998
Emergent Biosolutions Inc is listed in the Healthcare sector of the New York Börse with ticker EBS. The last closing price for Emergent Biosolutions was US$7,75. Over the last year, Emergent Biosolutions shares have traded in a share price range of US$ 5,615 to US$ 14,06.

Emergent Biosolutions currently has 51.596.296 shares in issue. The market capitalisation of Emergent Biosolutions is US$418,45 million. Emergent Biosolutions has a price to earnings ratio (PE ratio) of -39.08.

EBS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.212.65822784817.98.497.588890348.07843842CS
40.020.2472187886288.099.47.568578208.39287415CS
12-0.01-0.123152709368.129.667.53187493638.38950067CS
26-3.96-32.808616404312.0714.067.53188512509.6600168CS
521.9732.08469055376.1414.065.61510208689.16371399CS
156-0.33-3.909952606648.4415.11.4218914676.10984483CS
260-53.41-86.817295188661.5268.02811.42149270810.98338511CS

EBS - Frequently Asked Questions (FAQ)

What is the current Emergent Biosolutions Inc share price?
The current share price of Emergent Biosolutions Inc is US$ 8,11
How many Emergent Biosolutions Inc shares are in issue?
Emergent Biosolutions Inc has 51.596.296 shares in issue
What is the market cap of Emergent Biosolutions Inc?
The market capitalisation of Emergent Biosolutions Inc is USD 418,45M
What is the 1 year trading range for Emergent Biosolutions Inc share price?
Emergent Biosolutions Inc has traded in the range of US$ 5,615 to US$ 14,06 during the past year
What is the PE ratio of Emergent Biosolutions Inc?
The price to earnings ratio of Emergent Biosolutions Inc is -39,08
What is the cash to sales ratio of Emergent Biosolutions Inc?
The cash to sales ratio of Emergent Biosolutions Inc is 0,63
What is the registered address of Emergent Biosolutions Inc?
The registered address for Emergent Biosolutions Inc is 300 Professional Drive, Gaithersburg, Maryland, 20879
What is the Emergent Biosolutions Inc website address?
The website address for Emergent Biosolutions Inc is www.emergentbiosolutions.com
Which industry sector does Emergent Biosolutions Inc operate in?
Emergent Biosolutions Inc operates in the Pharmaceuticals sector

EBS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen